Dabigatran Etexilate Is Cost Effective for Stroke Prevention in Atrial Fibrillation in Real-World Clinical Practice

Dabigatran Etexilate Is Cost Effective for Stroke Prevention in Atrial Fibrillation in Real-World Clinical Practice
Thursday, March 24, 2011
By: Boehringer Ingelheim

Boehringer Ingelheim

A new economic analysis, published online in Thrombosis and Haemostasis, suggested that Boehringer Ingelheim's novel oral direct thrombin inhibitor dabigatran etexilate is cost-effective compared to current treatment options, particularly in real-world clinical practice.1,2

This cost-effectiveness was driven by superior prevention of ischemic stroke alongside a reduction in devastating intracranial bleeding by dabigatran etexilate compared to well-controlled warfarin, in patients with atrial fibrillation (AF).1 When dabigatran etexilate was compared against current care, including 'real-world' warfarin, it saved 4,783 Canadian dollars (CAD) on average per patient for prevention of events, such as stroke, and the subsequent associated follow-on costs.